All
RSSArticles
-
Widely Used in Asia, Cilostazol Appears Effective for Long-Term Secondary Stroke Prevention
Cilostazol is a phosphodiesterase 3 inhibitor widely used in Asia for secondary stroke prevention but approved for use in North America only for symptomatic peripheral vascular disease. It has been theorized that cilostazol might be beneficial in preventing the progression of small vessel disease in the brain and, therefore, may have a secondary effect in preventing vascular dementia.
-
Treatment of Central Retinal Artery Occlusion with Intravenous Thrombolysis
Central retinal artery occlusion is a serious threat to vision caused by interruption of the blood supply to the retina and leading to sudden, painless loss of vision in one eye. For 30 years there have been anecdotal reports and small case series suggesting that intravenous thrombolysis might be beneficial in this disorder, but none of the stroke treatment guidelines have incorporated thrombolysis as definitive treatment for this disorder.
-
Anticoagulation in Patients with Ischemic Stroke Related to Atrial Fibrillation, Following Reperfusion Therapy
Following ischemic stroke in patients with non-valvular atrial fibrillation, the timing to restart anticoagulation treatment is uncertain and controversial. In addition, there is little data available regarding timing to restart anticoagulation following reperfusion therapy with either systemic thrombolysis and/or mechanical thrombectomy.
-
Brachial Plexopathy Localization in Patients with Cancer
Brachial plexopathy associated with cancer may involve any region of the brachial plexus and can be distinguished from radiation-induced brachial plexopathy only by the use of high-resolution magnetic resonance imaging.
-
Clinical Trials of IL-6 Inhibitors for the Treatment of Neuromyelitis Optica Spectrum Disorders
In a randomized, placebo-controlled trial of neuromyelitis optica spectrum disorder patients, satralizumab monotherapy demonstrated a decrease in relapse rate when compared to placebo. In a randomized, open-label, multicenter trial of tocilizumab vs. azathioprine, treatment with tocilizumab demonstrated a decreased risk of a relapse compared to azathioprine.
-
We’d Love to Hear from You!
We’re always looking for ways to do better! Please take five minutes to complete our annual user survey.
-
FDA Releases Q&A for COVID-19 and Clinical Trials
The Food and Drug Administration recently released updated guidance on conducting clinical trials of medical products during the COVID-19 pandemic. The new version of the guidelines includes a question-and-answer section that clarifies some emergency changes affecting human research protection policies and procedures.
-
SBER Programs Face Challenges with Revised Common Rule
Social-behavioral-educational research programs have always faced challenges fitting their work into the parameters of human research protection rules and regulations devised with biomedical research in mind. But the revised Common Rule has produced new issues with informed consent.
-
IRB Members Can Build Good Relationships in Virtual Space
One long-time virtual IRB has learned how to develop camaraderie and rapport among IRB members without ever meeting in person — or seeing each other’s faces.
-
Keeping Open Dialogue Part of Virtual IRB Meeting Plan
A full-time virtual IRB gives advice on bringing IRB meetings online during the COVID-19 pandemic.